Mediwound ( (MDWD) ) has released its Q1 earnings. Here is a breakdown of the information Mediwound presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MediWound Ltd. is a global biotechnology company specializing in enzymatic therapies for non-surgical tissue repair, with a focus on products like NexoBrid for burn treatment and EscharEx for chronic wound debridement. In its first quarter of 2025, MediWound reported revenues of $4 million, with a reaffirmed full-year revenue guidance of $24 million. The company is advancing its VALUE Phase III trial for EscharEx in venous leg ulcers and expanding NexoBrid’s manufacturing capacity, expecting full operational capacity by the end of 2025. Key financial highlights include a gross profit of $0.7 million, an operating loss of $5.2 million, and a net loss of $0.7 million, showing improvement from the previous year due to non-cash financial income. Looking forward, MediWound is focused on maintaining its clinical and operational momentum, with strategic collaborations and manufacturing expansions aimed at supporting long-term growth.